Dr. Vose on Acalabrutinib/Pembrolizumab Combo in DLBCL

Video

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Julia M. Vose, MD, professor and chief in the Division of Oncology/Hematology at University of Nebraska Medical Center, discusses the rationale for the phase I/II trial of acalabrutinib (Calquence) plus pembrolizumab (Keytruda) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

As single agents, both acalabrutinib and pembrolizumab have shown activity in other types of lymphoma and their toxicities do not overlap. This makes them the combination of choice for patients with relapsed/refractory DLBCL, Vose explains.

She says that despite the low complete response rate and short duration of response seen overall in the study, several patients showed meaningful activity (>24 months) and the combination was well tolerated. This is rationale to explore the combination further.

<<< 15th International Conference on Malignant Lymphoma

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center